Spots Global Cancer Trial Database for tsc
Every month we try and update this database with for tsc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II | NCT06392009 | Tuberous Sclero... Focal Cortical ... | Radiprodil | 6 Months - 18 Years | GRIN Therapeutics, Inc. | |
| Regulating Together in Tuberous Sclerosis Complex | NCT06105736 | TSC Behavioral Symp... | Behavioral Inte... | 8 Years - 17 Years | University of North Carolina, Chapel Hill | |
| Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) | NCT00789828 | Tuberous Sclero... Subependymal Gi... | Everolimus Placebo | - | Novartis | |
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | NCT02635789 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel Placebo gel | 3 Years - | Nobelpharma | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC | NCT01767779 | Tuberous Sclero... | 1 Day - 6 Months | University of Alabama at Birmingham | ||
| Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | NCT06160310 | Tuberous Sclero... Lymphangioleiom... | - | Children's Hospital Medical Center, Cincinnati | ||
| JASPER Early Intervention for Tuberous Sclerosis | NCT03422367 | Tuberous Sclero... | JASPER | 6 Months - 40 Months | University of California, Los Angeles | |
| Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | NCT06160310 | Tuberous Sclero... Lymphangioleiom... | - | Children's Hospital Medical Center, Cincinnati | ||
| Remote Assessment and Intervention for Behavior Problems in Kids With TSC | NCT06311474 | Tuberous Sclero... | Parent-Child In... | 3 Years - 6 Years | University of California, Los Angeles | |
| A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | NCT05252585 | Renal Angiomyol... | Everolimus | 20 Years - 65 Years | Novartis | |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | NCT05104983 | Tuberous Sclero... Epilepsy | Sirolimus Placebo | 1 Day - 6 Months | Children's Hospital Medical Center, Cincinnati | |
| Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis | NCT01687179 | Lymphangioleiom... | "Sirolimus" and... "Sirolimus" and... | 18 Years - 85 Years | Brigham and Women's Hospital | |
| Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex | NCT01730209 | Tuberous Sclero... TSC Related Cog... TSC Related Aut... TSC Related Lea... | Everolimus Placebo | 4 Years - 15 Years | Erasmus Medical Center | |
| A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | NCT05252585 | Renal Angiomyol... | Everolimus | 20 Years - 65 Years | Novartis | |
| JASPER Early Intervention for Tuberous Sclerosis | NCT03422367 | Tuberous Sclero... | JASPER | 6 Months - 40 Months | University of California, Los Angeles | |
| Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex | NCT02098759 | TSC Tuberous Sclero... Epilepsy | epilepsy early ... | - 4 Months | Children's Memorial Health Institute, Poland | |
| Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC | NCT01767779 | Tuberous Sclero... | 1 Day - 6 Months | University of Alabama at Birmingham | ||
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Regulating Together in Tuberous Sclerosis Complex | NCT06105736 | TSC Behavioral Symp... | Behavioral Inte... | 8 Years - 17 Years | University of North Carolina, Chapel Hill | |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | NCT05104983 | Tuberous Sclero... Epilepsy | Sirolimus Placebo | 1 Day - 6 Months | Children's Hospital Medical Center, Cincinnati | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures | NCT04485104 | Seizure in Part... Seizure in Part... Seizure in Part... | GWP42003-P | 1 Month - 23 Months | Jazz Pharmaceuticals | |
| Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex | NCT02634931 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel | 3 Years - | Nobelpharma | |
| Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) | NCT01780441 | Tuberous Sclero... | 3 Months - 12 Months | Boston Children's Hospital | ||
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | NCT02635789 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel Placebo gel | 3 Years - | Nobelpharma | |
| Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) | NCT02461459 | Tuberous Sclero... Autism Disorder Intellectual Di... | 18 Months - | Boston Children's Hospital | ||
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | NCT02635789 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel Placebo gel | 3 Years - | Nobelpharma | |
| Basimglurant in Children, Adolescents, and Young Adults With TSC | NCT05059327 | Tuberous Sclero... | Basimglurant wi... Placebo with cr... | 5 Years - 30 Years | Noema Pharma AG |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
